<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854149</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT_AR_trial_01102018_v1.0</org_study_id>
    <nct_id>NCT03854149</nct_id>
  </id_info>
  <brief_title>Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study</brief_title>
  <acronym>PROTECT_AR</acronym>
  <official_title>A Prospective, Observational, Multicenter Study on the Safety and Efficacy of Apixaban for the Prevention of Thromboembolism in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onassis Cardiac Surgery Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mitera Children's Hospital, Athens, Greece</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of apixaban for the&#xD;
      prevention of thromboembolism in adult patients with congenital heart disease (CHD) and&#xD;
      non-valvular atrial arrhythmias (AA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with congenital heart disease (ACHD) represent a rapidly growing population&#xD;
      due to the progress of surgical techniques and optimal medical management. Non-valvular&#xD;
      atrial arrhythmias (AA) carries a significant burden for long-term morbidity and potentially&#xD;
      mortality in ACHD patients. AA occur three times more frequently in ACHD compared to the&#xD;
      general population. When complicating ACHD, AA convey a twofold increase in the risk for&#xD;
      stroke, contributing to an up to 100-fold higher prevalence of stroke in the ACHD population&#xD;
      compared to age-matched healthy controls. At present, the European Society of Cardiology&#xD;
      (ESC) Guidelines suggest oral anticoagulation (OAC) in all adult patients with AA and&#xD;
      intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle. In the&#xD;
      remaining ACHD patients with AA, OAC is suggested if CHA2DS2-Vasc (congestive heart failure,&#xD;
      hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular&#xD;
      disease, age 65 to 74 years, sex category) score is ≥1 (Class of recommendation IIa, level of&#xD;
      evidence C).&#xD;
&#xD;
      Non-vitamin K oral anticoagulants (NOACs) are increasingly preferred over vitamin-K&#xD;
      antagonists (VKAs) in most clinical scenarios due to improved safety (with regard to&#xD;
      intracranial and other major bleeding) and efficacy (prevention of embolic stroke or systemic&#xD;
      embolism) along with the convenience they offer for patients and physicians (fixed dose, no&#xD;
      food and drug interactions, no INR monitoring). On the other hand, scarce data is available&#xD;
      on the use of NOAC in ACHD.&#xD;
&#xD;
      In order to address this gap in evidence, we propose a prospective multicenter single arm,&#xD;
      observational cohort trial, which will provide data on the efficacy and safety of apixaban&#xD;
      used for the prevention of thromboembolism in ACHD patients with AA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Stroke, systemic or pulmonary arterial thromboembolism and intracardiac thrombosis.</measure>
    <time_frame>up to 48 months</time_frame>
    <description>The composite endpoint of all-cause stroke, systemic and pulmonary embolism and intracardiac thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Defined as clinically overt bleeding that is associated with:&#xD;
A fall in hemoglobin of 2 g/dL or more&#xD;
A transfusion of ≥2 units of packed red blood cells or whole blood&#xD;
Bleeding in a critical site: intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal&#xD;
Death (fatal bleeding)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Defined as new neurologic symptoms or deficit lasting less than 24 hours with no new infarction on neuroimaging (if available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Defined as the detection of a significant rise/fall of Troponin in association with symptoms of ischemia, ECG changes, proof of ischemia on imaging or intracoronary thrombus at angiography. [Fourth definition of myocardial infarction; European Society of Cardiology (ESC) 2018]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Cardiovascular deaths were classified as deaths due to: ischemic stroke, hemorrhagic stroke, systemic or pulmonary embolism, other cardiovascular (i.e., myocardial infarction, sudden death, heart failure) and unobserved deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Τhe composite of major and clinically relevant nonmajor bleeding</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Clinically relevant nonmajor bleeding bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>General quality of life</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Assessed with questionnaire SF-36</description>
  </other_outcome>
  <other_outcome>
    <measure>Apixaban persistence</measure>
    <time_frame>up to 48 months</time_frame>
    <description>The proportion of patients who were on apixaban at enrolment and continued receiving apixaban at the end of the study period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Apixaban adherence</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Assessed by reviewing electronic pharmacy prescription data</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Atrial Arrhythmia</condition>
  <condition>Thromboembolism</condition>
  <condition>Anticoagulants Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>Adults with CHD &amp; non-valvular atrial arrhythmias</arm_group_label>
    <description>Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with Congenital Heart Disease and Non-Valvular Atrial Arrhythmias who are&#xD;
        routinely treated with apixaban (i.e., new or ongoing users) for stroke prevention at any&#xD;
        health-care level in Greece&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged ≥18 years.&#xD;
&#xD;
          2. Presence of congenital heart disease (intracardiac repair, cyanosis, Fontan&#xD;
             palliation, or systemic right ventricle or other congenital heart disease).&#xD;
&#xD;
          3. Non-Valvular Atrial Arrhythmia (including at least one electrocardiographically&#xD;
             documented episode).&#xD;
&#xD;
          4. Signed written informed consent by the patient for participation in the study and&#xD;
             agreement to comply with the medication and the follow-up schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. moderate-to-severe mitral stenosis or mechanical valves&#xD;
&#xD;
          2. patient unwilling or unable to complete follow-up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios Giannakoulas, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgios Giannakoulas, MD, PhD</last_name>
    <phone>2310994830</phone>
    <phone_ext>0030</phone_ext>
    <email>ggiannakoulas@auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Frogoudaki, MD</last_name>
      <email>afrogou@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Frogoudaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sotiria Liori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mitera Children's Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aphrodite Tzifa, MD</last_name>
      <email>atzifa@mitera.gr</email>
    </contact>
    <investigator>
      <last_name>Aphrodite Tzifa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Centre</name>
      <address>
        <city>Athens</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sotiria Apostolopoulou, MD</last_name>
      <email>riapos@hol.gr</email>
    </contact>
    <investigator>
      <last_name>Sotiria Apostolopoulou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Ntzouvara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Giannakoulas, MD, PhD</last_name>
      <phone>2310994830</phone>
      <phone_ext>0030</phone_ext>
      <email>ggiannakoulas@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Giannakoulas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charalambos Karvounis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Rampidis, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioannis Doundoulakis, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anastasios Kartas, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Despoina Ntiloudi, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.hcs.gr/challenge.aspx</url>
    <description>CHALLENGE Registry</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 23, 2019</study_first_submitted>
  <study_first_submitted_qc>February 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>George Giannakoulas</investigator_full_name>
    <investigator_title>Assistant Professor - MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>NOAC</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Atrial arrhythmias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

